VTAK (Catheter Precision) Debt-to-Revenue : 4.91 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Catheter Precision Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Catheter Precision's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.35 Mil. Catheter Precision's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.54 Mil. Catheter Precision's annualized Revenue for the quarter that ended in Sep. 2024 was $0.38 Mil. Catheter Precision's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 4.91.

Catheter Precision Debt-to-Revenue Historical Data

The historical data trend for Catheter Precision's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catheter Precision Debt-to-Revenue Chart

Catheter Precision Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.49

18.86

102.91

0.84

Catheter Precision Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															0.40	0.73	0.77	2.17	4.91

Competitive Comparison of Catheter Precision's Debt-to-Revenue

For the Medical Devices subindustry, Catheter Precision's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Catheter Precision's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Catheter Precision's Debt-to-Revenue falls into.

Catheter Precision Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Catheter Precision's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.275	+	0.097)	/	0.442
	=	0.84

Catheter Precision's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.348	+	1.536)	/	0.384
	=	4.91

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Catheter Precision Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Catheter Precision's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Catheter Precision Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Catheter Precision Inc (AMEX:VTAK) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1670 Highway 160 West, Suite 205, Fort Mill, SC, USA, 29708

Website

https://www.catheterprecision.com

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Executives

David A Jenkins	director, officer: Executive Chairman of Board	P.O. BOX 682838, PARK CITY UT 84068
Steven K Passey	officer: Chief Financial Officer	3216 SOUTH HIGHLAND DRIVE, SUITE 200, SALT LAKE CITY UT 84117
James Joseph Caruso	director	28 FIRST AVE, SEASIDE PARK NJ 08752
Brian Conn	officer: Chief Financial Officer	MICROISLET, INC., 6370 NANCY RIDGE DRIVE, SUITE 112, SAN DIEGO CA 92121
Andrew C. Jackson	officer: CFO & Secretary	11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Jonathan Will Mcguire	director, officer: Chief Executive Officer	96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Susanne Meline	director	P.O. BOX 515381, #86506, LOS ANGELES CA 90051
Martin J Colombatto	director
Richard Jr Mejia	director	2200 FARADAY AVENUE, SUITE 100, CARLSBAD CA 92008
William R Enquist	director	11810 WILLS ROAD, ALPHARETTA GA 30009
Joan Stafslien	director	CAREFUSION CORPORATION, 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Daniel Horwood	officer: General Counsel	C/O RA MEDICAL SYTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Jeffrey J Kraws	officer: Co-President	3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Dean Irwin	director, 10 percent owner, officer: See Remarks	C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Martin Burstein	10 percent owner	C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011